- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.10. | ORION Corp. Reveals Rise In Q3 Bottom Line | 16 | RTTNews | ||
| 30.10. | ORION Corp. Q3 Income Rises | 6 | RTTNews | ||
| ORION OYJ A Aktie jetzt für 0€ handeln | |||||
| 28.10. | Orion Oyj: Orion Group Interim report January-September 2026: Strong financial performance and positive developments in the R&D pipeline | 298 | GlobeNewswire (Europe) | ORION CORPORATION INTERIM REPORT 1-9/2026 28 OCTOBER 2026 at 12:00 EET Orion Group Interim report January-September 2026: Strong financial performance and positive developments in the R&D pipeline... ► Artikel lesen | |
| 27.10. | Dividendenbekanntmachungen (27.10.2026) | 5.058 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AEON CO LTD ADR US0076271024 0,0003 USD EUR AEON CO LTD ADR US0076271024 0,0468 USD EUR AMBRA SA PLAMBRA00013 1,1 PLN 0,2498... ► Artikel lesen | |
| 26.10. | Orion Oyj: Changes in Orion Group's Executive Team as of 1 January 2027 | 419 | GlobeNewswire (Europe) | ORION CORPORATION STOCK EXCHANGE RELEASE - CHANGES BOARD/MANAGEMENT/AUDITORS 26 October 2026 at 13.00 EET Changes in Orion Group's Executive Team as of 1 January 2027 To accelerate the implementation... ► Artikel lesen | |
| 24.10. | Orion Oyj: Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence | 1.507 | GlobeNewswire (Europe) | ORION CORPORATION PRESS RELEASE 24 OCTOBER 2026 at 9.35 EEST Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk... ► Artikel lesen | |
| 21.10. | Orion Oyj Lifts FY26 Outlook | 610 | AFX News | HELSINKI (dpa-AFX) - Orion Oyj (ORNBV.HE), a Nordic pharmaceutical company, Tuesday said that it is raising its fiscal 2026 net sales and operating profit outlook as royalty income has increased... ► Artikel lesen | |
| 20.10. | Orion Oyj: Inside information: Orion upgrades full-year outlook for 2026 | 412 | GlobeNewswire (Europe) | ORION CORPORATION STOCK EXCHANGE RELEASE - INSIDE INFORMATION 20 OCTOBER 2026 at 20.20 EEST Inside information: Orion upgrades full-year outlook for 2026 Orion Corporation upgrades the full-year... ► Artikel lesen | |
| 19.10. | Dividendenbekanntmachungen (19.10.2026) | 9.265 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADENTRA INC CA00686A1084 0,16 CAD 0,1007 EUR ANADOLU EFES BIRACILIK VE MALT SANAYII A ... US0325232017 0,0036 USD EUR ANADOLU... ► Artikel lesen | |
| 14.10. | Orion Oyj: Orion publishes Interim Report for January-September 2026 and holds a webcast on 28 October 2026 | 5 | GlobeNewswire (USA) | ||
| 07.10. | Orion Oyj: 125,000 Orion Corporation A shares converted into B shares | 8 | GlobeNewswire (USA) | ||
| 06.10. | Orion Pharma, Qilu Partner On Pembrolizumab Biosimilar In Europe | 606 | AFX News | HELSINKI (dpa-AFX) - Orion Corp. (0M2N.L, ORNAV.HE, ORNBV.HE) and Qilu Pharma Europe have entered into an agreement to commercialise an intravenous (IV) pembrolizumab biosimilar in Europe.Pembrolizumab... ► Artikel lesen | |
| 06.10. | Orion Oyj: Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market | 377 | GlobeNewswire (Europe) | ORION CORPORATION PRESS RELEASE 6 OCTOBER 2026 at 9.00 EEST Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market Orion Corporation ("Orion... ► Artikel lesen | |
| 05.10. | Orion Oyj: Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company's first biologic candidate to reach clinical testing | 593 | GlobeNewswire (Europe) | ORION CORPORATION PRESS RELEASE 05 OCTOBER 2026 at 8:00am ET Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company's first biologic candidate to reach clinical... ► Artikel lesen | |
| 30.09. | Orion Oyj: Orion Corporation completed share acquisitions | 2 | GlobeNewswire (USA) | ||
| 04.09. | Orion Oyj: 102,000 Orion Corporation A shares converted into B shares | 4 | GlobeNewswire (USA) | ||
| 14.08. | ORION Corp. Reports Higher Revenue And Profit In Q2 2026 | 1.043 | AFX News | SEOUL (dpa-AFX) - ORION Corp. (271560.KS) on Friday reported revenue of KRW 893.59 billion for the second quarter of 2026, compared with KRW 777.17 billion in the same period of 2025. For the... ► Artikel lesen | |
| 10.08. | Orion Oyj: Orion's license partner Tenax Therapeutics' Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint | 951 | GlobeNewswire (Europe) | ORION CORPORATION STOCK EXCHANGE RELEASE - INSIDE INFORMATION 10 AUGUST 2026 at 14.05 EEST Orion's license partner Tenax Therapeutics' Phase 3 LEVEL trial of oral levosimendan in pulmonary... ► Artikel lesen | |
| 17.07. | ROUNDUP: Orion Q2 Profit Rises; Revises Outlook | 745 | AFX News | HELSINKI (dpa-AFX) - (Adds Outlook)For the full year, Orion Oyj (0M2N.L) now expects operating profit of EUR 650 million to EUR 750 million, compared with the previous expectation of EUR 600... ► Artikel lesen | |
| 17.07. | Orion Oyj Reveals Advance In Q2 Income | 784 | AFX News | HELSINKI (dpa-AFX) - Orion Oyj (0M2N.L) reported earnings for its second quarter that Increased, from last yearThe company's bottom line came in at EUR140.2 million, or EUR1 per share. This... ► Artikel lesen |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ELI LILLY | 1.281,60 | -0,17 % | Eli Lilly kauft AtaiBeckley für 2,8 Milliarden Dollar - wer behandelt künftig die Patienten? | ||
| INCYTE | 108,30 | +0,98 % | Incyte präsentiert auf der ASH 2026 neue Daten, die die Fortschritte im gesamten hämatologischen Portfolio verdeutlichen | Zu den neuen Daten zu myeloproliferativen Neoplasien (MPN) gehören INCA033989, Incytes "First-in-Class"-monoklonaler Antikörper, der auf mutiertes Calreticulin (mutCALR) abzielt, bei der Erstlinienbehandlung... ► Artikel lesen | |
| BACHEM | 87,25 | +0,75 % | EQS-News: Claros Technologies gibt die weitere geschäftliche Expansion nach Europa sowie den Einstieg in die pharmazeutische Produktion bekannt - nach einem erfolgreichen Pilotprojekt zur PFAS-Zerstörung bei der Bachem AG | EQS-News: Claros Technologies
/ Schlagwort(e): ESG/Expansion
Claros Technologies gibt die weitere geschäftliche Expansion nach Europa sowie den Einstieg in die pharmazeutische... ► Artikel lesen | |
| WUXI BIOLOGICS | 5,520 | -2,47 % | Der China-Schatz: Fresenius sichert sich 37 neue Biosimilar-Kandidaten | © Foto: Arne Dedert/dpaFresenius sichert sich über einen Exklusivvertrag mit WuXi Biologics Zugriff auf bis zu 37 neue Biosimilars. Die Pipeline könnte sich mehr als verdoppeln. DZ Bank und Jefferies... ► Artikel lesen | |
| DAIICHI SANKYO | 15,898 | +0,16 % | Asking More of Science: How Daiichi Sankyo Is Challenging Assumptions About the Future of Cancer Care | ||
| UCB | 291,20 | -1,15 % | Veeva Systems: UCB Selects Veeva Vault CRM | UCB Selects Veeva Vault CRM
Agentic CRM platform to drive unified engagement worldwidePLEASANTON, Calif., Nov. 4, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that UCB has committed... ► Artikel lesen | |
| ASTELLAS PHARMA | 14,600 | -0,68 % | Astellas, Immuneering Enter Pancreatic Cancer Trial Collaboration | TOKYO (dpa-AFX) - Japanese drugmaker Astellas Pharma Inc. (ALPMY) announced on Thursday that it has entered into a clinical trial collaboration and supply agreement with Immuneering Corp. (IMRX)... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen | |
| ORION | 102,50 | +0,20 % | Orion Oyj: Orion Group Interim report January-September 2026: Strong financial performance and positive developments in the R&D pipeline | ORION CORPORATION INTERIM REPORT 1-9/2026 28 OCTOBER 2026 at 12:00 EET Orion Group Interim report January-September 2026: Strong financial performance and positive developments in the R&D pipeline... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 14,600 | +0,55 % | Alliance Advisors LLC: Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences | Little Falls, New Jersey--(Newsfile Corp. - May 19, 2026) - Alliance Advisors is pleased to congratulate Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) on the successful completion of its tender offer... ► Artikel lesen | |
| GALDERMA GROUP | 208,60 | +1,56 % | Gewinnmitnahmen? Teppichetage von Galderma verkauft Aktienpakete in Millionenhöhe | ||
| AMPHASTAR | 26,420 | +1,50 % | Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026 | Net revenues of $207.6 million for the three months ended September 30, 2026GAAP net income of $37.8 million, or $0.87 per share, for the third quarterAdjusted non-GAAP net income of $49.3 million,... ► Artikel lesen | |
| HANSOH PHARMACEUTICAL | 3,887 | -1,27 % | EQS-News: Hansoh Pharma: 19,3 % Gewichtsverlust in Woche 48: Daten der Phase-III-Studie zu Olatorepatid, Hansohs dualem, biased GLP-1/GIP-Agonisten, auf der EASD-Tagung vorgestellt | EQS-News: Hansoh Pharma
/ Schlagwort(e): Sonstiges
19,3 % Gewichtsverlust in Woche 48: Daten der Phase-III-Studie zu Olatorepatid, Hansohs dualem, biased GLP-1/GIP-Agonisten,... ► Artikel lesen | |
| LIFEVANTAGE | 4,000 | -14,53 % | LifeVantage outlines $3M-$3.5M annualized platform spend as it plans 2027 digital launches | ||
| PHARMANUTRA | 84,20 | +3,19 % | Pharmanutra SpA Bottom Line Rises In Nine Months |
Das Unternehmen ORION OYJ A kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von +1,40 (+1,36 %) liegt der Kurs bei 104,20 Euro. Die Dividendendrendite beträgt aktuell +2,59 % (berechnet anhand der Ausschüttung von 2,70 Euro in den letzten 12 Monaten).
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ORION OYJ A finden Sie auf Wallstreet Online.